Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2802962 | 0.84 | L3MBTL1 (0.46) | L3MBTL1CNR2ALDH1A1 | |
| SCHEMBL24429434 | 0.83 | ALDH1A1 (0.48) | L3MBTL1CNR2TP53ALDH1A1NPSR1 | |
| SCHEMBL17393996 | 0.81 | L3MBTL1 (0.45) | L3MBTL1CNR2TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL27886350 | 0.80 | L3MBTL1 (0.42) | L3MBTL1CNR2ALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL24429407 | 0.79 | SMN1; SMN2 (0.50) | L3MBTL1CNR2TP53ALDH1A1SMN1; SMN2 | |
| SCHEMBL2804042 | 0.79 | L3MBTL1 (0.47) | L3MBTL1CNR2TP53ALDH1A1NPSR1 | |
| SCHEMBL29659970 | 0.74 | CNR2 (0.39) | L3MBTL1CNR2 | |
| SCHEMBL1817972 | 0.73 | TRPV4 (0.53) | L3MBTL1CNR2TP53ALDH1A1TRPV4 | |
| SCHEMBL1874207 | 0.73 | TRPV4 (0.49) | L3MBTL1TRPV4SMN1; SMN2GAA | |
| SCHEMBL289253 | 0.73 | TRPV4 (0.49) | L3MBTL1TP53ALDH1A1TRPV4NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010132016-A1 | BIS-(SULFONYLAMINO) DERIVATIVES FOR TREATMENT OF PAIN AND INFLAMMATION | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | L3MBTL1 2928/4885CNR2 400/4885TP53 3228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.